Human Genome Sciences (HGSI -8.3%) shares tumble pre-market after reporting disappointing data...

|By:, SA News Editor

Human Genome Sciences (HGSI -8.3%) shares tumble pre-market after reporting disappointing data from a Phase III study for its lupus drug Benlysta. Human Genome and partner GlaxoSmithKline (GSK +0.2%) say they still hope to file for U.S. and European regulatory approval for the product during Q2. (PR)